{"brief_title": "Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients", "brief_summary": "The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.", "condition": ["Lymphoma, T-Cell, Cutaneous", "Mycosis Fungoides", "Sezary Syndrome"], "intervention_type": ["Drug"], "intervention_name": ["ONTAK"], "criteria": "Inclusion Criteria: - Histopathologically confirmed recurrent or persistent CTCL as determined by reference pathology lab; - Patient must have had 1 to 3 prior CTCL therapies. Repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. Only 1 prior combination cytotoxic regimen is permitted. Topical or systemic steroids are not considered a therapy; - Interleukin-2 receptor (IL-2R) expression on at least 20% of tumor cells as determined by immunohistochemistry. - Stage IA - III disease and unlikely to progress during the first month on study. Life expectancy of at least 12 months. - Measurable or evaluable disease. Lymph node involvement no greater than LN2. No CTCL involvement of bone marrow. - No active CNS disease, kidney or liver disease, significant pulmonary disease, or cardiac disease. - No systemic infections; - Willingness to be randomized to a placebo treatment only arm; - ECOG performance status 0 or 1; Exclusion Criteria: \u2022 Patients must not have previously received treatment with DAB389IL-2 or DAB486IL 2 (previous candidate compound evaluated in a clinical setting).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Lymphoma", "Lymphoma, T-Cell", "Mycoses", "Mycosis Fungoides", "Sezary Syndrome", "Lymphoma, T-Cell, Cutaneous", "Denileukin diftitox"], "id": "NCT00050999"}